HSCT recipient with resolved infection of HBV
Conditions
Interventions
HB vaccine arm HBV DNA and anti-HBs antibody are monitored every 28 days, and preemptive nucleoside analogue is administered when reactivation of HBV is observed. Inoculations of HB vaccine are pla
Sponsors
National Center for Global Health and Medicine Genome Medical Science Project
The Japanese Data Center for Hematolopoietic Cell Transplantation SRL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patient is planed to undergo 1st hematopoietic stem cell transplantation (2) HBs antigen negative and anti-HBc antibody positive (3) more than 20 year-old and less than 70 year-old (4) Those patient who give written informed consent
Exclusion criteria
Exclusion criteria: (1) anti-HCV antibody negative (2) anti-HIV antibody negative (3) HBV DNA>=1.3 Log IU/mL (4) anti-HBc antibody negative (5) seroconversion of anti-HBc antibody negative to positive after infusion of blood product (6) previous HBV reactivation (7) previous history of treatment using nucleoside analogue, or plan to prescribe nucleoside analogue for prophylaxis (8) anaphylaxis for previous vaccine (9) conditioning regimen has been started for first HSCT (10) complication of severe infection (11) hemodialysis has been started or planed to be induced (12) uncontrollable diabetics, hypertension or heart failure (13) woman during pregnant or lactation (14) patient who plan to move or plan to be followed by other institute during 2-year after HSCT (15) patient who is not been considered to be eligible to the study by a doctor in charge by miscellaneous reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV reactivation | — |
Countries
Japan
Contacts
Public ContactMasahiro Onozawa
Hokkaido University Hospital Department of Hematology
Outcome results
None listed